Sucralose, Your Gut, and Vitiligo — The Sweet Lie We Don’t Want to Hear (Ep. 55)

Deep Dive in Vitiligo Is Back — And Yes, AI Made Us Busier

After a brief hiatus, the Deep Dive in Vitiligo podcast returns with a packed lineup of new episodes covering vitiligo science, lifestyle, advocacy, and technology. In this update, Yan Valle explains where the podcast has been, why AI didn’t save nearly as much time as promised, and what’s coming next—including * the Jackson–Thomas–Harlow Effect * children’s books * coffee and red wine * smoking and vaping * vitamin D megadosing * career success * nail changes * deodorants * and the growing role of artificial intelligence in healthcare. The voices may be AI. The research, writing, editing, and judgment remain entirely human. Subscribe now and join us for a new season of conversations at the intersection of skin, science, technology, and the human experience.

The State of Vitiligo 2025: A Fast-Moving Field With Slow-Moving Funding (Ep. 57)

In this closing 2025 episode, we unpack four decades of National Institute of Health (NIH) data, compare vitiligo’s budget to other autoimmune and skin diseases, and explain the “industry twist”: tiny public dollars helped build the science, while the commercial market is now booming. We also look at the big paradox: vitiligo research helped spark major ideas in modern medicine (think immune pathways that later shaped blockbuster therapies), yet the shared infrastructure vitiligo now needs — US-based biobanks, registries, and longitudinal cohorts — remains fragmented. Meanwhile, the commercial side is moving fast, with a billion-dollar market and crowded pipelines. Read the full report in two parts: The Vitiligo Paradox – Common Disease, Rare Funding [https://vrfoundation.org/news_items/the-vitiligo-paradox-common-disease-rare-funding] Who Gets to Do Vitiligo Science? [https://vrfoundation.org/news_items/who-gets-to-do-vitiligo-science]

VR Foundation — 2025 Year-End Report (Ep. 56)

In this year-end episode, we walk through what VRF built in 2025 — from global advocacy and new research to education, AI support tools, and community partnerships — plus the uncomfortable truths that shaped our priorities for 2026. Read the full report here: https://vrfoundation.org/news_items/vr-foundation-2025-year-end-report [https://vrfoundation.org/news_items/vr-foundation-2025-year-end-report]

Sucralose, Your Gut, and Vitiligo — The Sweet Lie We Don’t Want to Hear (Ep. 55)

Vitiligo may show up on your skin, but the drama starts lower down — in your gut, where trillions of microbes run the show. When that microscopic circus gets out of tune, your immune system can lose its mind. Enter sucralose — that “harmless” fake sugar in your diet soda and protein shake. It tastes sweet, promises zero calories, and might just be quietly gaslighting your gut bacteria. The result? More inflammation, less balance, and a very confused immune system. In this episode: * How sucralose messes with your microbiome * Why that matters if your immune system’s already on edge * The fine line between calming inflammation and killing defense * And why “sugar-free” doesn’t mean consequence-free Your gut’s a garden, not a chemistry set. Sucralose won’t nuke it overnight — but it might slowly evict the good tenants and hand the keys to the troublemakers. Full story: Sucralose, Your Gut, and Vitiligo – Should We Worry? [https://vrfoundation.org/news_items/sucralose-your-gut-and-vitiligo-should-we-worry]

Topical Rapamycin — Vitiligo’s Next Big Hope? (Ep. 54)

From Easter Island soil to modern skin science — meet rapamycin, the molecule that might just change vitiligo care. Once known mainly as an anti-rejection drug for organ transplants, rapamycin is now being tested as a topical treatment that could both calm the immune attack and help pigment return. Early studies look promising: minimal side effects, slow but steady repigmentation, and surprisingly good tolerance. In this episode, we explore: * How rapamycin rewires the skin’s immune balance * Why it’s called both a suppressor and a rejuvenator * What Phase II trials are revealing so far * And whether this “longevity drug” might also restore color to the skin It’s too early to call it a breakthrough — but this little molecule from a far-off island might just be the next quiet revolution in vitiligo therapy. Full story: Topical Rapamycin: Could This Be Vitiligo’s Next Big Breakthrough? [https://vrfoundation.org/news_items/topical-rapamycin-could-this-be-vitiligos-next-big-breakthrough]